The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Sep 02, 2026
Snapshot (as of Sep 02, 2026): Novartis AG (NVS) pays a $4.55 annual dividend ($1.14 quarterly), yielding 2.83% at $161.25/share. Next ex-dividend date 2026-03-11. 6 consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.83%
Annual Dividend: $4.55 per share
Payout Ratio: 67.8%
Ex-Dividend Date: 2026-03-11
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 26
Novartis AG dividend investors are looking at a Basel-based pharmaceutical company that develops and markets prescription medicines across oncology, immunology, neuroscience, and cardiovascular diseases. NVS currently pays a 2.99% dividend yield. Shareholders receive $4.5749 per share annually in quarterly payments, with the next ex-dividend date set for March 11, 2026. A beta of 0.462 points to low price volatility, which suits income investors who prioritize capital preservation alongside yield.
Novartis AG pays out 67.8% of earnings as dividends, a payout ratio classified as elevated (60–75%). That level is supported by a product portfolio anchored in prescription medicines for oncology and cardiovascular diseases, categories that carry recurring demand by nature. Novartis AG dividend safety faces its main pressure point from that same payout ratio: at 67.8%, there is limited room to absorb an earnings decline without squeezing the dividend.
Novartis AG dividend history shows a CAGR of 4.7% per year from 2011 to 2025. Per-share payments grew from $2.1084 to $3.9940 over that window (2026 figures are partial and excluded from the CAGR calculation). The largest annual increase in the window was 18.5% in 2020, though the history also includes two years, 2016 and 2019, where the per-share amount dipped slightly year-over-year. For income investors, 4.7% annual growth is meaningful but not fast enough to dramatically expand real purchasing power over a short holding period.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +6.0% | $3.36 (2022) | $3.99 (2025) |
| 5-Year | +5.6% | $3.04 (2020) | $3.99 (2025) |
| 10-Year | +4.7% | $2.52 (2015) | $3.99 (2025) |
NVS fits dividend investors who want a moderate (2–4%) yield from a large pharmaceutical business with a long payment history. The current 2.99% yield sits above the 5-year average of 2.24%, which means buyers today are locking in a historically above-average income rate. The trade-off is a 67.8% payout ratio that leaves less cushion than lower-payout peers, and a 4.7% annual growth rate that is steady but not aggressive. Six consecutive years of dividend increases add a degree of predictability. What an investor gets here is above-average yield for this stock's own history, paired with moderate growth and an elevated payout that warrants watching.
| Payment Date | Amount per Share |
|---|---|
| 2026-03-11 | $4.7730 |
| 2025-03-12 | $3.9940 |
| 2024-03-07 | $3.7400 |
| 2023-03-09 | $3.4690 |
| 2022-03-08 | $3.3570 |
| 2021-03-04 | $3.3780 |
| 2020-03-03 | $3.0420 |
| 2019-03-04 | $2.5672 |
| 2018-03-06 | $2.6676 |
| 2017-03-01 | $2.4606 |
| Year | Total Dividends |
|---|---|
| 2026 | $4.7730 |
| 2025 | $3.9940 |
| 2024 | $3.7400 |
| 2023 | $3.4690 |
| 2022 | $3.3570 |
Project income from NVS with the NVS dividend calculator or track your full portfolio with the dividend tracker.